RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.
| Revenue (Most Recent Fiscal Year) | $1.12M |
| Net Income (Most Recent Fiscal Year) | $-11.17M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 27.43 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -823.98% |
| Net Margin (Trailing 12 Months) | -823.98% |
| Return on Equity (Trailing 12 Months) | -135.03% |
| Return on Assets (Trailing 12 Months) | -101.92% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.15 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.95 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.51 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.15 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.32 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.33 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 45.10M |
| Free Float | 40.98M |
| Market Capitalization | $40.84M |
| Average Volume (Last 20 Days) | 0.31M |
| Beta (Past 60 Months) | 1.01 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.13% |
| Percentage Held By Institutions (Latest 13F Reports) | 3.10% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |